# US 2014/0155395 A1 · Substituted aza-bicyclic imidazole derivatives useful as trpm8 receptor modulators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0155395 A1
- Document ID: US20140155395A1
- Status: Published application
- Kind: A1
- Application number: 14/172,395
- Filed: 2014-02-04
- Published: 2014-06-05
- Earliest claimed: 2010-03-05
- Assignees: Janssen Pharmaceutica NV
- Applicants: Janssen Pharmaceutica, NV
- Inventors: Mark R. Player; Raul Calvo; Jinsheng Chen; Sanath Meegalla; Daniel Parks; William Parsons; Scott Ballentine; Shawn Branum
- Web page: https://patentgrep.com/patent/US20140155395A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07C 53/18: containing fluorine
- C07C 309/04: containing only one sulfo group
- C07D 473/00: Heterocyclic compounds containing purine ring systems
- C07D 487/04: Ortho-condensed systems
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present invention is directed to substituted aza-bicyclic imidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by TRP M8, including for example, inflammatory pain, inflammatory hyperalgesia, inflammatory hypersensitivity condition, neuropathic pain, neuropathic cold allodynia, inflammatory somatic hyperalgesia, inflammatory visceral hyperalgesia, cardiovascular disease aggravated by cold and pulmonary disease aggravated by cold.

## Claims

### Claim 1

A compound of formula (I)
wherein
R1 is selected from the group consisting of hydrogen, fluoro, chloro, fluorinated C1-4alkyl and fluorinated C1-4 alkoxy;
R2 is hydrogen;
is selected from the group consisting of
wherein R3 is selected from the group consisting of hydrogen, chloro, cyano, C1-4alkyl, fluorinated C1-4alkyl, C1-4alkoxy, fluorinated C1-4alkoxy, —O—(CH2)2—OH, —O—CH2—CO2H, —O—(CH2)2—O—(C1-4alkyl), —O—CH2-(fluorinated C1-2 alkyl), —O—(CH2)2—NRARB and —NRARB;
wherein RA and RB are each independently selected from the group consisting of hydrogen and C1-4alkyl;
alternatively RA and RB are taken together with the nitrogen atom to which they are bound to form a ring structure selected form the group consisting of pyrrolidin-1-yl, piperidin-1-yl, piperazin-1-yl, 4-methyl-piperidin-1-yl, 4-methyl-piperazin-1-yl and morpholin-4-yl;
Q is an optionally substituted ring structure selected from the group consisting of formulas (a) through (h)
wherein R5 is C1-4alkyl; R6 is selected from the group consisting of C1-4alkyl and fluorinated C1-4alkyl; and R7 is selected from the group consisting of hydrogen, chloro, fluoro, cyano, C1-4alkyl and C1-4 alkoxy;
wherein R8 and R9 are each independently selected from the group consisting of C1-4alkyl;
wherein R10 is C1-4alkyl; and R11 is selected from the group consisting of hydrogen and cyano;
wherein R12 and R13 are each independently selected from the group consisting of hydrogen and C1-4alkyl;
wherein R14 is C1-4alkyl;
wherein R15 is C1-4alkyl; and R16 is selected from the group consisting of hydrogen, chloro and bromo; and
wherein R17 is C1-4alkyl;
or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

A compound as in claim 1, wherein
R1 is selected from the group consisting of hydrogen, fluoro, chloro, fluorinated C1-2 alkyl and fluorinated C1-2alkoxy;
R2 is hydrogen;
is selected from the group consisting of
wherein R3 is selected from the group consisting of hydrogen, chloro, cyano, C1-2alkyl, fluorinated C1-2alkyl, C1-4alkoxy, fluorinated C1-2alkoxy, —O—(CH2)2—OH, —O—CH2—CO2H, —O—(CH2)2—O—(C1-4alkyl), —O—CH2-(fluorinated C1-2alkyl), —O—(CH2)2—NRARB and —NRARB;
wherein RA and RB are each independently selected from the group consisting of hydrogen and C1-2alkyl; alternatively RA and RB are taken together with the nitrogen atom to which they are bound to form a ring structure selected from the group consisting of pyrrolidin-1-yl, piperidin-1-yl, piperazin-1-yl, 4-methyl-piperazin-1-yl and morpholin-4-yl;
Q is an optionally substituted ring structure selected from the group consisting of formulas (a) through (h)
wherein R5 is C1-4alkyl; R6 is selected from the group consisting of C1-4alkyl and fluorinated C1-4alkyl; and R7 is selected from the group consisting of hydrogen, chloro, fluoro, cyano, C1-2alkyl and C1-2alkoxy;
wherein R8 and R9 are each independently selected from the group consisting of C1-4alkyl;
wherein R10 is C1-4alkyl; and R11 is selected from the group consisting of hydrogen and cyano;
wherein R12 and R13 are each independently selected from the group consisting of hydrogen and C1-4alkyl;
wherein R14 is selected from the group consisting of C1-4alkyl;
wherein R15 is C1-4alkyl; and R16 is selected from the group consisting of hydrogen, chloro and bromo; and
wherein R17 is C1-2alkyl;
or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 2)

A compound as in claim 2, wherein
R1 is selected from the group consisting of hydrogen, chloro, fluoro, trifluoromethyl and trifluoromethoxy;
R2 is hydrogen;
is selected from the group consisting of
wherein R3 is selected form the group consisting of hydrogen, chloro, cyano, C1-2alkyl, trifluoromethyl, C1-4alkoxy, —O—(CH2)2—OH, —O—CH2—CO2H, —O—(CH2)2—O—(C1-2alkyl), O—CH2-(fluorinated C1-2 alkyl), —O—(CH2)2—NRARB, pyrrolidin-1-yl, piperidin-1-yl, piperazin-1-yl, 4-methyl-piperazin-1-yl and morpholin-4-yl;
and wherein RA and RB are each an independently selected C1-2alkyl; alternatively RA and RB are taken together with the nitrogen atom to which they are bound to form a ring structure selected from the group consisting of pyrrolidin-1-yl, piperidin-1-yl, piperazin-1-yl, 4-methyl-piperazin-1-yl and morpholin-4-yl;
Q is an optionally substituted ring structure selected from the group consisting of formulas (a) through (h)
wherein R5 is C1-4alkyl; R6 is selected from the group consisting of C1-4alkyl and fluorinated C1-4alkyl; and R7 is selected from the group consisting of hydrogen, chloro, fluoro, cyano, C1-2alkyl and C1-2alkoxy;
wherein R8 and R9 are each independently selected from the group consisting of C1-4alkyl;
wherein R10 is C1-4alkyl; and R11 is selected from the group consisting of hydrogen and cyano;
wherein R12 is hydrogen and R13 is selected from the group consisting of C1-4alkyl;
wherein R14 is selected from the group consisting of C1-4alkyl;
wherein R15 is C1-4alkyl; and R16 is selected from the group consisting of hydrogen and bromo; and
wherein R17 is C1-2alkyl;
or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 3)

A compound as in claim 3, wherein
R1 is selected from the group consisting of hydrogen, chloro, fluoro, trifluoromethyl and trifluoromethoxy;
R2 is hydrogen;
is selected from the group consisting of
Q is selected from the group consisting of 1-methyl-3-tert-butyl-pyrazol-5-yl, 1-methyl-3-tert-butyl-4-chloro-pyrazol-5-yl, 1-methyl-3-tert-butyl-4-fluoro-pyrazol-5-yl, 1-methyl-3-tert-butyl-4-cyano-pyrazol-5-yl, 1-methyl-3-trifluoromethyl-4-chloro-pyrazol-5-yl, 1-methyl-3-tert-butyl-4-methoxy-pyrazol-5-yl, 1-methyl-3-(1,1-dimethyl-2-fluoro-ethyl)-4-chloro-pyrazol-5-yl, 1-tert-butyl-pyrazol-4-yl, 1-tert-butyl-5-methyl-pyrazol-4-yl, 1-methyl-3-tert-butyl-imidazol-2-yl, 3-tert-butyl-isoxazol-5-yl, 3-tert-butyl-4-cyano-isoxazol-5-yl, 4-isopropyl-thien-2-yl, 5-isopropyl-thien-3-yl, 4-tert-butyl-fur-2-yl, 4-tert-butyl-5-bromo-fur-2-yl, and
or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 4)

A compound as in claim 4, wherein
R1 is selected from the group consisting of chloro, fluoro, trifluoromethyl and trifluoromethoxy;
R2 is hydrogen;
is selected from the group consisting of
Q is selected from the group consisting of 1-methyl-3-tert-butyl-pyrazol-5-yl, 1-methyl-3-tert-butyl-4-chloro-pyrazol-5-yl, 1-methyl-3-tert-butyl-4-fluoro-pyrazol-5-yl, 1-methyl-3-tert-butyl-4-cyano-pyrazol-5-yl, 1-methyl-3-tert-butyl-4-methoxy-pyrazol-5-yl, 1-methyl-3-(1,1-dimethyl-2-fluoro-ethyl)-4-chloro-pyrazol-5-yl, 3-tert-butyl-isoxazol-5-yl, 3-tert-butyl-4-cyano-isoxazol-5-yl, 4-isopropyl-thien-2-yl, 5-isopropyl-thien-3-yl, 4-tert-butyl-fur-2-yl, 4-tert-butyl-5-bromo-fur-2-yl and
or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 4)

A compound as in claim 4, wherein
R1 is selected from the group consisting of chloro, fluoro, trifluoromethyl and trifluoromethoxy;
R2 is hydrogen;
is selected from the group consisting of
Q is selected from the group consisting of 1-methyl-3-tert-butyl-4-chloro-pyrazol-5-yl, 1-methyl-3-tert-butyl-4-cyano-pyrazol-5-yl, 1-methyl-3-(1,1-dimethyl-2-fluoro-ethyl)-4-chloro-pyrazol-5-yl, 3-tert-butyl-isoxazol-5-yl and
or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof.

### Claim 7

(canceled)

### Claim 8 (depends on 4)

A compound as in claim 4, wherein
R1 is selected from the group consisting of chloro and trifluoromethyl;
R2 is hydrogen;
is selected from the group consisting of
Q is selected from the group consisting of 1-methyl-3-tert-butyl-4-chloro-pyrazol-5-yl and 1-methyl-3-tert-butyl-4-cyano-pyrazol-5-yl;
or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof.

### Claim 9

(canceled)

### Claim 10 (depends on 8)

A compound as in claim 8, wherein the pharmaceutically acceptable salt thereof is selected from the group consisting of sodium salt, potassium salt and methanesulfonic acid salt.

### Claim 11 (depends on 1)

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of claim 1.

### Claim 12 (depends on 1)

A process for making a pharmaceutical composition comprising mixing a compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 13 (depends on 1)

A method for inhibiting Icilin and CCI comprising administering to a mammal an effective amount of a compound as in claim 1.

### Claim at position 14

14-31. (canceled)

### Claim 32 (depends on 4)

A compound as in claim 4, wherein
R1 is selected from the group consisting of chloro and trifluoromethyl; R2 is hydrogen; R3 is —OCH3; Q is selected from the group consisting of 1-methyl-3-tert-butyl-4-chloro-pyrazol-5-yl and 1-methyl-3-tert-butyl-4-cyano-pyrazol-5-yl;
or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof.

### Claim at position 16

33-35. (canceled)
